Fatigue - Pipeline Review, H2 2016
Summary
Global Markets Directs, Fatigue - Pipeline Review, H2 2016, provides an overview of the Fatigue pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Fatigue
- The report reviews pipeline therapeutics for Fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fatigue therapeutics and enlists all their major and minor projects
- The report assesses Fatigue therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fatigue
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fatigue
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fatigue Overview 6
Therapeutics Development 7
Pipeline Products for Fatigue - Overview 7
Fatigue - Therapeutics under Development by Companies 8
Fatigue - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Fatigue - Products under Development by Companies 12
Fatigue - Companies Involved in Therapeutics Development 13
BioLite, Inc. 13
Biovista Inc. 14
Grifols, S.A. 15
Hemispherx Biopharma, Inc. 16
MultiCell Technologies, Inc. 17
Fatigue - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
(lofepramine hydrochloride + phenylalanine) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
alpha-1 proteinase inhibitor (human) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
BLI-1402 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Recombinant A1PI - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
rintatolimod - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Fatigue - Dormant Projects 43
Fatigue - Product Development Milestones 44
Featured News & Press Releases 44
Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology 44
Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke 45
Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen 45
Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study 46
Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms 47
Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe 47
Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Divisions Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations 48
May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations 49
May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets 49
Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 50
Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 51
Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries 51
Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen 51
Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen 52
Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55
List Of Tables
Number of Products under Development for Fatigue, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Fatigue - Pipeline by BioLite, Inc., H2 2016 13
Fatigue - Pipeline by Biovista Inc., H2 2016 14
Fatigue - Pipeline by Grifols, S.A., H2 2016 15
Fatigue - Pipeline by Hemispherx Biopharma, Inc., H2 2016 16
Fatigue - Pipeline by MultiCell Technologies, Inc., H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Assessment by Combination Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Fatigue - Dormant Projects, H2 2016 43
Lisst Of Figures
Number of Products under Development for Fatigue, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 20
Number of Products by Stage and Targets, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 22
Number of Products by Stage and Mechanism of Actions, H2 2016 22
Number of Products by Routes of Administration, H2 2016 24
Number of Products by Stage and Routes of Administration, H2 2016 24
Number of Products by Molecule Types, H2 2016 26
Number of Products by Stage and Molecule Types, H2 2016 26
